Shares of Leap Therapeutics Inc (NASDAQ:LPTX) have received a consensus broker rating score of 1.50 (Buy) from the two analysts that cover the company, Zacks Investment Research reports. One analyst has rated the stock with a buy rating and one has issued a strong buy rating on the company.
Analysts have set a twelve-month consensus price target of $15.50 for the company and are forecasting that the company will post ($0.51) earnings per share for the current quarter, according to Zacks. Zacks has also given Leap Therapeutics an industry rank of 199 out of 265 based on the ratings given to its competitors.
Separately, Zacks Investment Research cut Leap Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, January 12th.
A hedge fund recently bought a new stake in Leap Therapeutics stock. Sabby Management LLC bought a new position in Leap Therapeutics Inc (NASDAQ:LPTX) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 89,350 shares of the company’s stock, valued at approximately $558,000. Sabby Management LLC owned 0.72% of Leap Therapeutics at the end of the most recent reporting period. 3.25% of the stock is currently owned by institutional investors.
About Leap Therapeutics
Leap Therapeutics, Inc, formerly HealthCare Pharmaceuticals, Inc, is a clinical-stage biopharmaceutical company. The Company engages in acquiring and developing therapeutics in cancer biology. Its lead product candidates for use in clinical trials include TRX518 and DKN-01. DKN-01 is a monoclonal antibody targeting Dickkopf-related protein 1 (DKK1).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Leap Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.